Literature DB >> 22889668

Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer.

Christos Perisanidis1, Fritz Wrba, Anita Brandstetter, Gabriela Kornek, David Mitchell, Rudolf Seemann, Edgar Selzer, Rolf Ewers, Martin Filipits.   

Abstract

The aim of this study was to evaluate the impact of expression of epidermal growth factor receptor (EGFR), mesenchymal-epithelial transition factor (c-Met), and insulin-like growth factor receptor 1 (IGF-1R) protein on response to treatment and survival in patients with oral and oropharyngeal squamous cell carcinoma (SCC). EGFR, c-Met, and IGF-1R immunohistochemical (IHC) scores were generated based on the incidence and intensity of expression of the biomarkers evaluated in paraffin-embedded sections of biopsy specimens taken before treatment from 113 patients given neoadjuvant chemoradiotherapy followed by resection for primary locally advanced oral and oropharyngeal SCC. Correlations were assessed between the IHC of the biomarkers and the patients' clinicopathological variables using Spearman's rank test. Cox's regression models were used to evaluate the impact of EGFR, c-Met, and IGF-1R, expression on survival. Almost all the patients showed expression of EGFR, c-Met, and IGF-1R (99%, 100%, and 100%, respectively). None of the biomarkers examined predicted response to neoadjuvant chemoradiotherapy or were associated with survival. In multivariate analysis, age (p=0.05), alcohol consumption (p=0.03), and pathological size/extent of the primary tumour after neoadjuvant treatment (ypT) status (p=0.009) were significantly associated with recurrence-free survival. Age (p=0.02) and alcohol consumption (p=0.02) were independently associated with overall survival. Although none of the biomarkers evaluated could be used as prognostic indicators, their common expression suggested a strong rationale for targeting EGFR, c-Met, and IGF-1R in the treatment of oral and oropharyngeal SCC.
Copyright © 2012 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889668     DOI: 10.1016/j.bjoms.2012.06.009

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  4 in total

1.  Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.

Authors:  Gregor Heiduschka; Anja Grah; Felicitas Oberndorfer; Rudolf Seemann; Alexander Kranz; Gabriela Kornek; Fritz Wrba; Dietmar Thurnher; Edgar Selzer
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

Review 2.  Impact of targeting insulin-like growth factor signaling in head and neck cancers.

Authors:  Kirsten H Limesand; Alejandro Martinez Chibly; Andrew Fribley
Journal:  Growth Horm IGF Res       Date:  2013-06-29       Impact factor: 2.372

Review 3.  Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma.

Authors:  Paolo Bossi; Carlo Resteghini; Nicholas Paielli; Lisa Licitra; Silvana Pilotti; Federica Perrone
Journal:  Oncotarget       Date:  2016-11-08

4.  High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer.

Authors:  F Zagouri; Z Bago-Horvath; F Rössler; A Brandstetter; R Bartsch; C A Papadimitriou; C Dimitrakakis; A Tsigginou; I Papaspyrou; A Giannos; M-A Dimopoulos; M Filipits
Journal:  Br J Cancer       Date:  2013-02-19       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.